Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.
Academic Article
Overview
abstract
Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2- breast cancer, which represents ∼70% of all cases.
